1. Randomized double-blind clinical studies of ularitide and other vasoactive substances in acute decompensated heart failure: a systematic review and meta-analysis
- Author
-
Wolf-Georg Forssmann, Stephan B. Felix, Jan Schnitker, and Veselin Mitrovic
- Subjects
medicine.medical_specialty ,Acute decompensated heart failure ,medicine.drug_class ,business.industry ,Central venous pressure ,Hemodynamics ,030204 cardiovascular system & hematology ,Placebo ,medicine.disease ,03 medical and health sciences ,0302 clinical medicine ,Meta-analysis ,Internal medicine ,Heart failure ,Natriuretic peptide ,medicine ,Cardiology ,030212 general & internal medicine ,Cardiology and Cardiovascular Medicine ,business ,Pulmonary wedge pressure - Abstract
AIMS Acute decompensated heart failure (ADHF) has a poor prognosis and limited treatment options. No direct comparisons between ularitide-a synthetic natriuretic peptide being evaluated in ADHF-and other vasoactive substances are available. The aim of this meta-analysis was to determine haemodynamic effect sizes from randomized double-blind trials in ADHF. METHODS AND RESULTS Eligible studies enrolled patients with ADHF requiring hospitalization and haemodynamic monitoring. Patients received 24-48 h of infusion with a vasoactive substance or comparator. Primary outcome measure was pulmonary artery wedge pressure (PAWP). Treatment effects were quantified as changes from baseline using mean differences between study drug and comparator. Results were analysed using random-effects (primary analysis) and fixed-effects meta-analyses. Twelve randomized, double-blind studies were identified with data after 3, 6, and 24 h of treatment (n = 622, 644, and 644, respectively). At 6 h, significant PAWP benefits for ularitide over placebo were seen (Hedges' g effect size, -0.979; P
- Published
- 2018
- Full Text
- View/download PDF